Bem-vindo ao Hub de Congressos em Oncologia da Boehringer Ingelheim
Para a Boehringer Ingelheim, o cuidado com o câncer é pessoal - Hoje e para as futuras gerações. Nosso compromisso de longo prazo com a oncologia é buscar a ciência de ponta para desenvolver tratamentos inovadores contra o câncer em diferentes tipos de tumores.
Publication @ ESMO 2024
Epidemiological and genomic features of patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with HER2/ERBB2 mutations within and outside the tyrosine kinase domain (TKD)
Author(s): Le X et al.
Tumor type(s): NSCLC
Compound/Target: N/A
Tumor type(s): NSCLC
Compound/Target: N/A
Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Author(s): Wermke et al.
Tumor type(s): Solid tumors
Compound/Target: DLL3/CD3 TcE
Tumor type(s): Solid tumors
Compound/Target: DLL3/CD3 TcE
Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Author(s): Harrington et al.
Tumor type(s): Solid tumors
Compound/Target: STING agonist
Tumor type(s): Solid tumors
Compound/Target: STING agonist
Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
Author(s): Champiat et al.
Tumor type(s): Solid tumors
Compound/Target: VSV-GP
Tumor type(s): Solid tumors
Compound/Target: VSV-GP
First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 study
Author(s): Oliva et al.
Tumor type(s): Solid tumors
Compound/Target: VSV-GP
Tumor type(s): Solid tumors
Compound/Target: VSV-GP
WCLC 2024
Industry Sponsored Symposium—Emerging Therapies in Clinical Practice: What are the Patient Perspectives on the Future of Lung Cancer Treatment?
Chair: Ernest Nadal
Speakers:
Christine Lovely
Solange Peters
John Heymach
Speakers:
Christine Lovely
Solange Peters
John Heymach
Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC-L
Author(s): Wermke et al.
Tumor type(s): NETs
Compound/Target: DLL3/CD3 TcE
Tumor type(s): NETs
Compound/Target: DLL3/CD3 TcE
Efficacy and Safety of Brigimadlin, a MDM2-p53 Antagonist, in Patients with Advanced Lung Adenocarcinoma
Author(s): Yamamoto et al.
Tumor type(s): NSCLC
Compound/Target: MDM2-p53
Tumor type(s): NSCLC
Compound/Target: MDM2-p53
Publication @ ASCO 2024
A Phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM)
Author(s): Sarkaria et al.
Tumor type(s): GBM
Compound/Target: MDM2-p53
Tumor type(s): GBM
Compound/Target: MDM2-p53
DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
Tumor type(s): SCLC
Compound/Target: DLL3/TcE
Tumor type(s): SCLC
Compound/Target: DLL3/TcE
A Phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors
Author(s): Doi et al.
Tumor type(s): Solid tumors
Compound/Target: B7-H6/CD3 TcE
Tumor type(s): Solid tumors
Compound/Target: B7-H6/CD3 TcE
Phase I, open-label dose escalation to investigate the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors
Author(s): Tolcher et al.
Tumor type(s): Solid tumors
Tumor type(s): Solid tumors
Publication @ AACR 2024
MRAS the forgotten member of the GTPase superfamily plays a role in KRASG12Ci resistance
Author(s): Hoffmann et al.
Tumor type(s): Solid tumors
Compound/Target: MRAS
Tumor type(s): Solid tumors
Compound/Target: MRAS
KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models
Author(s): Peng et al.
Tumor type(s): Solid tumors
Compound/Target: MRAS
Tumor type(s): Solid tumors
Compound/Target: MRAS
KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications
Author(s): Tedeschi et al.
Tumor type(s): Solid tumors
Compound/Target: MRAS
Tumor type(s): Solid tumors
Compound/Target: MRAS
The ADC payload PNU-159682 is highly active in a wide range of cancer indications by inducing DNA damage and cell death via a distinct mode of action
Author(s): Kaiser et al.
Tumor type(s): Solid tumors
Compound/Target: MRAS
Tumor type(s): Solid tumors
Compound/Target: MRAS
Beamion LUNG-2
DAREON-5
